Successful Phase I and Phase II trials against breast cancer were announced in May and December 2014 respectively. As of early 2016,<unk>  was involved in 3 Phase III clinical trials: * The JUNIPER Study is comparing<unk>  against erlotinib in patients with stage IV non-small-cell lung carcinoma Due to collect data until September 2017. * The MONARCH 2 study is investigating the effectiveness of<unk>  in combination with fulvestrant for women with breast cancer. It is due to end in Feb 2017. In March 2017, Eli Lilly announced that it had met its primary endpoint of superior progression-free survival (PFS) over placebo plus fulvestrant in patients with estrogen receptor positive and HER2 negative advanced or metastatic breast cancer. This result led to the September 2017 FDA approval. * The MONARCH 3 study is investigating the effectiveness of<unk> , plus either anastrozole or letrozole, as a first-line treatment for women with breast cancer. The trial is expected to end in June 2017.
Abemaciclib
Trilaciclib
Cemiplimab
Nirsevimab
Regdanvimab
Lirentelimab
Obiltoxaximab
Sotrovimab